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Background: Antiretroviral therapy (ART) and oral pre-exposure prophylaxis (PrEP) are effective in reducing HIV
transmission in heterosexual adults. The epidemiologic impact and cost-effectiveness of combined prevention
approaches in resource-limited settings remain unclear.
Methods: We develop a dynamic mathematical model of the HIV epidemic in South Africa’s adult population. We
assume ART reduces HIV transmission by 95% and PrEP by 60%. We model two ART strategies: scaling up access for
those with CD4 counts ≤ 350 cells/μL (Guidelines) and for all identified HIV-infected individuals (Universal). PrEP
strategies include use in the general population (General) and in high-risk individuals (Focused). We consider
strategies where ART, PrEP, or both are scaled up to 100% of remaining eligible individuals yearly. We measure
infections averted, quality-adjusted life-years (QALYs) gained and incremental cost-effectiveness ratios over 20 years.
Results: Scaling up ART to 50% of eligible individuals averts 1,513,000 infections over 20 years (Guidelines) and
3,591,000 infections (Universal). Universal ART is the most cost-effective strategy at any scale ($160-$220/QALY
versus comparable scale Guidelines ART expansion). General PrEP is costly and provides limited benefits beyond
ART scale-up ($7,680/QALY to add 100% PrEP to 50% Universal ART). Cost-effectiveness of General PrEP becomes
less favorable when ART is widely given ($12,640/QALY gained when added to 100% Universal ART). If feasible,
Focused PrEP is cost saving or highly cost effective versus status quo and when added to ART strategies.
Conclusions: Expanded ART coverage to individuals in early disease stages may be more cost-effective than current
guidelines. PrEP can be cost-saving if delivered to individuals at increased risk of infection.
Keywords: ART, Cost-effectiveness analysis, HIV epidemic, Oral pre-exposure prophylaxisBackground
Despite recent successes in reducing the global burden
of HIV, an estimated 2.3 million people were newly in-
fected in 2012, with 1.6 million in sub-Saharan Africa
[1,2]. The expansion of combination antiretroviral ther-
apy (ART) for treatment of HIV-infected individuals has
been closely linked with mortality reductions in many
sub-Saharan African countries [3]. Expansion of ART
was accomplished in large part with development assist-
ance programs funded by donor governments and phil-
anthropic organizations [4]. However, assistance for HIV* Correspondence: ssabina@stanford.edu
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2014has leveled since 2010, and declined in 2012, increasing
the need to consider the value of investments in direc-
ting scarce resources for HIV treatment and prevention
[5].
While many HIV programs in sub-Saharan Africa
invested heavily in expanding ART coverage, scientific
advances in recent years have resulted in four new HIV
prevention interventions: male circumcision, topical
microbicides, oral pre-exposure prophylaxis (PrEP), and
ART for prevention [6-10]. Among these, PrEP and ART
have generated particular interest because of their effi-
cacy, safety, and, coming on the heels of the expansion
in ART for HIV treatment, possibility of large-scale
implementation.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Key model parameters with source and ranges
(epidemic and behavioral characteristics, intervention
scale and effectiveness, health and intervention costs)
Parameter Value and
source
Range
Prevalence
HIV prevalence 17.9% [24] 17.2% to 18.3%
ART
Initial access to ART 40% [24] 35% to 45%
ART quit rate (annual) 0.02 Est 0.00 to 0.20
Sexual transmission reduction 95% [9] 50.0% to 99.0%
PrEP
PrEP quit rate (annual) 0.05 Est 0.00 to 0.20
Sexual acquisition reduction 60% [15,16] 10% to 90%
Sexual behavior
Number of sexual partners per year -
general
1.5 [25], Est 1 to 2
Number of sexual partners per year -
high risk
4 Est 3 to 5
Condom usage rate - general 25% [25], Est 10% to 40%
Condom usage rate - high risk 5% Est 0% to 10%
Condom effectiveness 90% [26] 85.0% to 95.0%
Annual costs (US$)
Non-HIV medical costs 200 100 to 300
HIV costs 1,000 [27] 800 to 1200
ART cost 150 [28,29] 100 to 200
PrEP cost 80 [28,29] 50 to 250
ART, antiretroviral therapy; PrEP, pre-exposure prophylaxis.
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tional studies, gained widespread legitimacy with the re-
lease of the HPTN052 trial results, which demonstrated
that early use of ART in sero-discordant couples re-
duced HIV transmission by 96% [9]. This finding sup-
ported the notion that epidemic control can be achieved
by expanding treatment to all those infected, regardless
of disease stage. Indeed, real-world examples outside of
clinical trials support the effectiveness of expanded ART
in preventing HIV infections [11]. By comparison, World
Health Organization guidelines recommended initiating
treatment when the CD4+ T-cell count is at or below
350 cells/μL [12]. More recently, the guidelines have
been expanded to include a broader population, al-
though country-specific guidelines lag behind [13,14].
Even in South Africa, where national guidelines support
ART for more individuals than any resource-limited
country, it is unclear when ART initiation would expand
to those with higher CD4 cell counts.
Two recent clinical trials have shown that uninfected
heterosexual individuals receiving an oral daily fixed-
dose combination of tenofovir disoproxil fumarate and
emtricitabine have a 63% to 73% reduced chance of ac-
quiring HIV [15,16]. Another trial demonstrated similar
effectiveness among men who have sex with men [8].
However, two trials conducted among African women
had study arms stopped for futility, with strong evidence
suggesting that the lack of efficacy was due to poor
adherence to study medication [17,18]. Despite these
concerns, oral PrEP is currently considered for policy
implementation in developing countries [19,20]. A prior
analysis considered use of PrEP only in heterosexual
sero-discordant couples, a situation when the uninfected
partner is at high risk of acquiring HIV, and found it can
be a potentially cost-saving intervention [21]. Other
studies analyzed a limited number of scale-up scenarios
and had shorter time horizons [22]. One study estimat-
ing the cost-effectiveness of ART for prevention (without
PrEP) uses a long time frame [23]. We studied the popu-
lation health outcomes and cost-effectiveness of imple-
menting expanded ART coverage and oral PrEP in a
setting with a heavy HIV burden.Methods
Overview
We built a dynamic compartmental model to represent
the HIV epidemic in South Africa’s adult population.
Key model parameters are shown in Table 1. The model
follows individuals’ health based on their infection sta-
tus, HIV disease stage, and ART or PrEP use. Full de-
tails of the model structure are provided in Additional
file 1 – Model details. Our main outcome measures
include infections averted, costs, and quality-adjustedlife years (QALYs) for each strategy, and the relative
cost-effectiveness of strategies.
Intervention scale-up strategies
We considered strategies where ART, PrEP, or both are
scaled up to recruit 25%, 50%, 75% or 100% of remai-
ning eligible individuals annually. For ART scale-up, we
considered strategies where ART was offered either to
individuals with CD4 cell counts ≤350 cells/μL only
(Guidelines), or to all identified HIV-infected individuals
(Universal) following a national testing campaign [30].
Thus, the 100% Guidelines strategy models outcomes
under full implementation of the current HIV treatment
guidelines, whereas the 100% Universal strategy reflects
the outcomes under an ideal ‘Universal Test and Treat’
program [12,31].
To investigate the role of PrEP in controlling South
Africa’s HIV epidemic, we considered its use in the gen-
eral adult population (General). We also investigated the
health and economic outcomes of using PrEP only in in-
dividuals at high-risk of acquiring HIV, defined here as
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condom use (Focused).Antiretroviral therapy
For the Guidelines strategy, we used a treatment eligi-
bility threshold of 350 cells/μL. In the base case (status
quo), 40% of treatment-eligible individuals receive ART,
and PrEP is not used [24]. We assumed that 10% of un-
treated treatment-eligible individuals start ART each
year. For the Universal strategy, any infected individual
identified and linked to care started ART.
ART is associated with both personal and transmission
benefits. Treated individuals have a longer remaining life
expectancy than untreated individuals (41.3 remaining
years for a 15-year-old if treatment is initiated early, ver-
sus 12.2 if untreated) [32,33]. HIV-related mortality rates
for each disease stage and ART status are in Additional
file 1 – Model details: Table S2. In addition, treated indi-
viduals are 95% less likely to infect their sexual partners
[9]. We assumed a 2% annual rate of loss-to-follow-up
throughout the time horizon. Although studies report a
higher rate of loss-to-follow-up in the short term, our
estimate is consistent with long-term experience, and
the higher efforts to retain patients in care [34,35]. Indi-
viduals who discontinue ART do not re-start treatment.Pre-exposure prophylaxis
For the General strategies, we assumed that all unin-
fected adults in the population are eligible to start PrEP.
While achieving high rates of PrEP coverage among the
entire population may be unfeasible for practical rea-
sons, we explored these possibilities to gain insight and
establish an upper bound for the benefits that could be
achieved with a large-scale PrEP program. In the Fo-
cused strategies, we assumed PrEP is offered only to a
population of 3 million uninfected individuals at highest
risk for acquiring HIV. This limited approach may ren-
der PrEP more feasible. We adjusted the risk profile of
the ineligible uninfected population in the Focused strat-
egy to match the overall population risk in the General
strategy.
We assumed uninfected individuals taking PrEP have
a 60% lower chance of acquiring HIV from an infected
sexual partner [15,16]. Because of the uncertainty over
PrEP’s real-world effectiveness highlighted in recent tri-
als, we broadly varied PrEP’s effectiveness in the sensi-
tivity analysis (10% to 90%) [17,18,36]. We assumed a
5% annual drop-out rate beyond the non-adherence
that is reflected in our estimate of PrEP effectiveness.
We also assumed that individuals who were infected
while on PrEP and later placed on ART had similar
benefits from treatment as those who never received
PrEP [15].Model structure
We divided South Africa’s adult population (15 to 49
years old, 26.3 million people) into 11 groups defined by
HIV disease stage (uninfected, CD4 count >350 cells/μL,
200 to 350 cells/μL, and <200 cells/μL), ART status (un-
treated, treated, and lost-to-follow-up), and PrEP status
(receiving or not receiving PrEP). A schematic diagram
of the model is included in Additional file 1 – Model
details.
HIV transmission and progression
We modeled heterosexual HIV transmission based on
the average number of annual partnerships per individ-
ual, assuming random homogeneous mixing in the
population. The annual probability of HIV transmission
in a partnership depends on the disease stage and ART
use of the infected partner, PrEP use by the uninfected
partner, and the rate of condom use and effectiveness.
HIV progression rates prior to and while receiving
ART were based on published studies from South Africa
[32,33]. ART was assumed to reduce mortality and lower
infectivity. We assumed no significant differences in dis-
ease progression rates for individuals who previously re-
ceived PrEP or for those who discontinued ART versus
individuals who were never treated.
Model calibration
Our model was calibrated to match information about
South Africa’s HIV epidemic, including initial HIV pre-
valence (17.9%), HIV incidence (1.4%), and population
growth [24,37]. Prevalence in individuals entering the
model at age 15 was estimated at 5% [25]. Using this
data, we estimated that HIV prevalence will decline to
10.4% over the next 20 years, due to a reduction in inci-
dence from 1.4% to 0.8%, while population growth will
average 1.1% annually.
Health outcomes and costs
We measured costs and QALYs for each strategy over 20
years, discounted at 3% annually. We included costs and
benefits incurred over the time horizon, plus discounted
future lifetime costs and QALYs incurred by the popula-
tion at the end of the time horizon.
We assumed lower quality of life as HIV progresses,
and that ART increases quality of life by 10% of the dif-
ference between uninfected and infected untreated indi-
viduals, to include both the benefits and the side effects
of ART.
We assumed annual ART costs of $150, and annual
PrEP costs of $80, reflecting the reduced prices of HIV
drugs accessible in South Africa [28,29]. All individuals
incurred an annual non-HIV medical cost of $200. In
addition, HIV-infected individuals incurred $1,000 in
HIV-related annual medical costs [27].
Table 2 Outcomes over 20 years of various strategies to scale up single or combination HIV prevention and treatment programs: Guidelines antiretroviral
therapy (individuals with CD4 cell counts ≤350 cells/μL only), Universal antiretroviral therapy (all HIV-infected individuals), General pre-exposure prophylaxis
(general population), Focused pre-exposure prophylaxis (individuals at high risk of acquiring HIV)
ART Guidelines portfolios Base
case
(50% Guidelines ART,
0% General PrEP)
(50% Guidelines ART,
50% General PrEP)
(50% Guidelines ART,
100% General PrEP)
(100% Guidelines ART,
0% General PrEP)
(100% Guidelines ART,
50% General PrEP)
(100% Guidelines ART,
100% General PrEP)
Total Population 28,899,757 30,584,812 31,140,505 31,243,269 31,155,266 31,559,954 31,637,147
HIV population 3,010,186 2,952,938 1,957,738 1,857,875 2,924,495 2,038,587 1,946,176
HIV prevalence 10.4% 9.7% 6.3% 5.9% 9.4% 6.5% 6.2%
PrEP entry 0% 0% 50% 100% 0% 50% 100%
ART entry
(late and advanced) 10% 50% 50% 50% 100% 100% 100%
ART entry
(early) 0% 0% 0% 0% 0% 0% 0%
Started ART 1,898,565 4,291,707 3,525,062 3,400,388 4,983,325 4,178,534 4,048,308
Total QALYs
(millions) 939 982 1,003 1,007 998 1,015 1,017
Total costs
($ billions) $282.2 $299.8 $343.5 $349.0 $306.0 $350.8 $356.5
Infections averted 1,512,972 3,545,397 3,826,716 2,030,990 3,751,962 3,993,700
CE ratio $413 $958 $992 $408 $914 $954
ART Universal portfolios Base
case
(50% Universal ART,
0% General PrEP)
(50% Universal ART,
50% General PrEP)
(50% Universal, 100%
General PrEP)
(100% Universal ART,
0% General PrEP)
(100% Universal ART,
50% General PrEP)
(100% Universal ART,
100% General PrEP)
Total Population 28,899,757 31,957,916 32,099,883 32,135,197 32,344,976 32,424,302 32,444,183
HIV population 3,010,186 2,429,248 2,020,691 1,965,384 2,372,222 2,045,369 2,002,584
HIV prevalence 10.4% 7.6% 6.3% 6.1% 7.3% 6.3% 6.2%
PrEP entry 0% 0% 50% 100% 0% 50% 100%
ART entry
(late and advanced) 10% 50% 50% 50% 100% 100% 100%
ART entry
(early) 0% 50% 50% 50% 100% 100% 100%
Started ART 1,898,565 5,605,789 4,997,687 4,883,560 5,946,284 5,442,264 5,354,623
Total QALYs
(millions) 939 1,025 1,031 1,033 1,037 1,041 1,042
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Table 2 Outcomes over 20 years of various strategies to scale up single or combination HIV prevention and treatment programs: Guidelines antiretroviral
therapy (individuals with CD4 cell counts ≤350 cells/μL only), Universal antiretroviral therapy (all HIV-infected individuals), General pre-exposure prophylaxis
(general population), Focused pre-exposure prophylaxis (individuals at high risk of acquiring HIV) (Continued)
Total costs
($ billions) $282.2 $309.1 $360.2 $366.2 $312.3 $365.7 $372.1
Infections averted 3,591,057 4,356,210 4,494,263 4,014,941 4,579,560 4,675,735
CE ratio $314 $849 $902 $307 $819 $876
Focused PrEP portfolios Base
case
(10% Guidelines ART,
50% Focused PrEP)
(10% Guidelines ART,
100% Focused PrEP)
(50% Guidelines ART,
100% Focused PrEP)
(100% Guidelines ART,
100% Focused PrEP)
(50% Universal ART,
100% Focused PrEP)
(100% Universal ART,
100% Focused PrEP)
Total Population 28,899,757 29,582,098 30,075,564 31,218,742 31,624,528 32,147,612 32,457,488
HIV population 3,010,186 2,232,122 1,743,582 1,983,526 2,059,891 2,010,021 2,038,731
HIV prevalence 10.4% 7.55% 5.8% 6.4% 6.5% 6.3% 6.3%
PrEP entry 0% 50% 100% 100% 100% 100% 100%
ART entry
(late and advanced) 10% 10% 10% 50% 100% 50% 100%
ART entry
(early) 0% 0% 0% 0% 0% 50% 100%
Started ART 1,898,565 1,639,299 1,454,123 3,455,184 4,104,640 4,897,716 5,362,426
Total QALYs
(millions) 939 962 978 1,006 1,016 1,033 1,042
Total costs
($ billions) $282.2 $277.1 274.9 292.9 299.8 307.9 313.3
Infections averted 1,837,744 3,084,508 3,642,543 3,840,111 4,468,827 4,663,411
CE ratio Cost saving Cost saving $163 $229 $276 $302
General PrEP
portfolios
Base
case
(10% Guidelines ART,
50% General PrEP)
(10% Guidelines ART,
100% General PrEP)
Total Population 28,899,757 29,970,799 30,151,535
HIV population 3,010,186 1,693,209 1,579,445
HIV prevalence 10.4% 5.65% 5.24%
PrEP entry 0% 50% 100%
ART entry
(late and advanced) 10% 10% 10%
ART entry
(early) 0% 0% 0%
Started ART 1,898,565 1,485,240 1,420,126
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Table 2 Outcomes over 20 years of various strategies to scale up single or combination HIV prevention and treatment programs: Guidelines antiretroviral
therapy (individuals with CD4 cell counts ≤350 cells/μL only), Universal antiretroviral therapy (all HIV-infected individuals), General pre-exposure prophylaxis
(general population), Focused pre-exposure prophylaxis (individuals at high risk of acquiring HIV) (Continued)
Total QALYs
(millions) 939 975 980
Total costs
($ billions) $282.2 $323.9 $329.6
Infections averted 2,998,344 3,381,214
CE ratio $1,172 $1,158
ART, antiretroviral therapy; CE, cost -effectiveness; PrEP, pre-exposure prophylaxis; QALY, quality-adjusted life-year.
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Our model suggests that, under the status quo, 5,400,000
individuals will become newly infected, 5,600,000 infected
individuals will die of HIV-related causes, and 1,900,000
infected individuals will start ART over the next 20 years.
Table 2 summarizes the results of the key scale-up stra-
tegies considered.Health benefits of scaling up ART and PrEP
Figure 1 presents the number of HIV infections averted
and incremental costs versus the status quo for 100%
scale-up of all strategies considered, individually and in
combination. In general, strategies involving UniversalFigure 1 HIV infections averted and incremental costs versus
the status quo with 100% scale-up for single or combination
programs over 20 years. (A) Infections averted over 20 years with
100% scale-up for single or combination programs. (B) Incremental
costs versus status quo over 20 years with 100% scale-up for single
or combination programs. Strategies include: Guidelines ART
(individuals with CD4 cell counts ≤350 cells/μL only), Universal ART
(all HIV-infected individuals), General PrEP (general population), and
Focused PrEP (individuals at high risk of acquiring HIV). Bars 1 and 2
show results of ART programs alone, 3 and 4 show results of PrEP
programs alone, and bars 5 to 8 show results of pairwise combinations
of ART and PrEP programs. ART strategies indicated by bar color:
Guidelines - red; Universal - orange; Status quo - no color. PrEP
strategies indicated by bar outline: General - solid line;
Focused - dashed line; Status quo - no line.ART scale-up avert more infections than strategies in-
volving General PrEP for the same rate of scale-up.
In the extreme scenario of 100% Universal ART with-
out PrEP, 75% of new infections are averted over 20 years,
whereas 100% coverage with Guidelines ART averts 38%
of new infections. Without PrEP, up to 50% more people
start treatment in the Universal ART strategies compared
to the corresponding Guidelines strategies, and 2 to 3.4
times as many infections are averted, depending on pro-
gram scale (Table 2).
Scaling up General PrEP alone to 100% while keeping
ART at current recruitment levels would avert 63% of
new infections over 20 years. Most of PrEP’s benefits are
achieved with General PrEP programs with less aggres-
sive recruitment rates; increasing PrEP recruitment rate
from 50% to 100% in the general population for any
given ART level averts only an additional 2% to 7% of
new infections. This is because a significant proportion
of uninfected individuals will start PrEP over the time
horizon even with a less aggressive program recruitment,
and the incremental benefits of an initially less aggres-
sive program approach the benefits of a more aggressive
program over time. Figure 2 shows the infections averted
by all combinations of General PrEP and Guidelines
ART (Figure 2A) or Universal ART (Figure 2B). Note
that as indicated in Figure 2B, a 10% Universal ART pro-
gram offers incremental benefits versus the status quo
due to expanded ART eligibility criteria (1,530,000 infec-
tions averted); adding General PrEP averts up to an add-
itional 2,270,000 infections.
Implementing PrEP in 50% of the uninfected popu-
lation in the presence of Guidelines ART programs
averted 61% to 69% of new infections, depending on
the scale of the ART program, versus 16% to 38% for
Guidelines ART alone. The marginal benefit of PrEP was
smaller when added to Universal ART programs, since
treating those with early HIV reduces the size of the
population that transmits HIV. Thus, 50% PrEP incre-
mental to Universal ART strategies averted 75% to 85%
of new infections, versus 53% to 75% for Universal ART
alone. This suggests that Universal ART and General
PrEP function as partial substitutes and the benefits of
PrEP may be more significant if Universal ART cannot
be accomplished. If it is achievable, Focused PrEP can be
an effective intervention: 100% Focused PrEP required
reaching 10% of the adult population, and averted 57%
of all new infections even without any further ART
scale-up. When added to 50% ART programs, Focused
PrEP averted a significant number of additional infec-
tions. Scaling up to 50% Guidelines ART and 100% Fo-
cused PrEP averted 2.4 times as many infections as the
ART program alone. These effects were smaller for lar-
ger ART programs and Universal ART, but in all scenar-
ios Focused PrEP averted 20% or more incremental HIV
Figure 2 Infections averted over 20 years with portfolios of scaled-up ART and PrEP. (A) Infections averted over 20 years with portfolios of
scaled-up Guidelines ART (individuals with CD4 cell counts≤ 350 cells/μL only) and General PrEP (general population). (B) Infections averted over
20 years with portfolios of scaled up Universal ART (all HIV-infected individuals) and General PrEP (general population).
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These results, however, critically depend on the ability to
identify the high-risk population and the effectiveness of
PrEP in this group, both of which are uncertain.
Cost-effectiveness
Universal ART had higher total costs, but also added sig-
nificantly more QALYs than Guidelines ART: Universal
ART cost $310 to $320 per QALY gained versus the sta-
tus quo, whereas Guidelines ART scale-up cost $410 to
$420 per QALY gained versus the status quo, with total
costs as well as benefits lower than the corresponding
Universal ART strategy. Figure 3 shows the benefits
(QALYs) and costs for single and combination programs
(Guidelines and Universal ART, General and Focused
PrEP).
With our base case assumptions of PrEP effectiveness,
strategies consisting of Focused PrEP alone were cost-saving compared to the status quo and offered signifi-
cant benefits. Combinations of Focused PrEP and ART
dominated ART alone, offering greater benefits at lower
costs: Universal ART scale-up to 100% in addition to Fo-
cused PrEP cost $150 per QALY gained. This was also
the most effective of all strategies (Table 2). However, if
Focused PrEP is infeasible, Universal ART is the alterna-
tive with the most attractive cost-effectiveness profile.
We estimated that General PrEP strategies would cost
$1,200 per QALY gained compared to the status quo.
For similar levels of benefit, General PrEP strategies
were more costly than ART programs. Adding 50% Gen-
eral PrEP to Guidelines ART scenarios gained QALYs
versus ART alone at costs between $1,600 per QALY
gained (for 25% Guidelines ART) and $2,650 per QALY
gained ( for 100% Guidelines ART). When added to Uni-
versal ART, 50% General PrEP added QALYs at $4,300
per QALY gained (25% Universal), but becomes more
Figure 3 Cost-effectiveness (quality-adjusted life-years versus total costs over 20 years) of 100% scale-up for single or combination
programs. Guidelines ART (individuals with CD4 cell counts ≤350 cells/μL only), Universal ART (all HIV-infected individuals), General PrEP (general
population), Focused PrEP (individuals at high risk of acquiring HIV). ART strategies indicated by dot shape: Guidelines - triangle; Universal
- diamond; Status quo - X mark. PrEP strategies indicated by dot color: General - black; Focused - gray. There is no PrEP in the status quo.
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programs (100% Universal).
While all strategies met traditional thresholds of cost-
effectiveness, our analysis suggests that some combina-
tions of strategies are much more attractive, given South
Africa’s gross domestic product per capita of $10,700
[38].
Sensitivity analysis
We performed extensive one-way sensitivity analyses
on all model parameters. We found that the results
varied with the effectiveness of the two interventions,
discontinuation rate for both, the cost of PrEP, the
number of sexual partners, and the rates of condom
usage in the population. However, the same alterna-
tives were preferred in terms of infections averted and
cost-effectiveness. In particular, we found that a PrEP ef-
fectiveness of 10% limited the cost savings of Focused
PrEP by 60% and reduced the cost-effectiveness of Ge-
neral PrEP by 50%.
Higher rates of PrEP attrition played little role in the
effects of the programs, assuming enough recruitment
to the program occurred to compensate for the attrition.
Higher rates of ART attrition (which made individuals
ineligible for ART) did not significantly decrease the
cost-effectiveness of ART scale-up, even at relatively
high levels (10% versus 2% in the base case).
The Focused PrEP strategy was no longer cost-saving
for costs of PrEP above $150. This price increase may
reflect additional costs to target high-risk individuals,
improve adherence, and monitor for adverse effects of
PrEP. To be as cost-effective as universal ART ($310 per
QALY), Focused PrEP annual cost would be $260 perperson, and $580 to cost as much per QALY ($1,200 per
QALY) as General PrEP at $80 in the base case.
Discussion and conclusions
We have presented an analysis of the effectiveness and
cost-effectiveness of two promising antiretroviral-based
HIV prevention technologies: ART and PrEP. We found
that targeting PrEP to individuals at particularly high
risk of infection may be cost-saving, but that if identify-
ing high-risk HIV-negative individuals is not practical,
then implementing universal treatment, regardless of
scale, would be the most cost-effective ART intervention
to reduce HIV transmission in South Africa. Our ana-
lysis is unique in considering the joint outcomes and
cost-effectiveness of implementing ART and PrEP for
HIV control.
We found that scaling up ART programs provided
greater value than untargeted PrEP programs. Compared
with the status quo, scaling up ART, either according to
current guidelines or with universal treatment, appeared
more cost-effective than scaling up untargeted PrEP.
Moreover, implementing PrEP in the general population
was never preferable to increasing ART coverage before
ART coverage reached 100%.
We have also shown that scaling up ART according to
current guidelines is less cost-effective than scaling up
universal treatment. Universal treatment averted more
infections than current guidelines even at relatively small
program scales. Scaling up ART according to guidelines
is still considered cost-effective in South Africa according
to thresholds articulated in the Commission on Macro-
economics and Health [38]. However, universal treatment
was associated with a greater number of infections averted
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resources relative to the status quo, and the results got in-
creasingly attractive as we considered longer planning ho-
rizons. When looking at the results for 10 years, Universal
ART appeared less favorable (while still cost-effective), at
$490 per QALY gained versus status quo. Taking into ac-
count benefits and costs over 20 years, this cost was $310
per QALY. Hence, Universal ART becomes more attrac-
tive if we consider the long-term impact, and the effects
may become even stronger with longer horizons. We
chose to use a 20-year time horizon because, unlike longer
horizons, this time frame is still considered relevant for
practical decision-making.
Our analysis suggests that despite the effectiveness of
oral PrEP, its costs make it a relatively low-value alterna-
tive if used in the general population. If, however, it can
be targeted to individuals at higher risk of acquiring HIV
and adherence can be maintained, then PrEP can poten-
tially be cost-saving. The effectiveness of PrEP remains
uncertain, as suggested by the recent mixed results of
clinical trials and the challenges with adherence. Our
sensitivity analyses showed that providing PrEP to high-
risk populations can be cost-saving as long as PrEP ef-
fectiveness is greater than 10%.
Our analysis has clear implications for resource prio-
ritization between ART and PrEP; however, its limi-
tations are important to note. Scaling up ART or PrEP
programs requires a substantial budget investment at a
time of global economic uncertainty. Our analysis can-
not determine whether these resources would be avail-
able, only that some investments provide greater returns
than others (for example, Universal ART relative to
Guidelines ART). For those reasons, we explored a wide
range of implementation scales. In addition, there is con-
siderable uncertainty associated with the long-term epi-
demic impact of universal treatment [39]. To explore this
issue, we performed sensitivity analyses on parameters af-
fecting the effectiveness of ART programs, such as re-
duction in infectivity if receiving ART, and the rates of
attrition from the program. Additional uncertainty is re-
lated to the potential consequences of sustained PrEP,
both in terms of individual toxicities and its implications
for resistance and future treatment options. As more data
become available, model assumptions and structure may
need to be further refined to incorporate these findings.
Finally, our model was based on South African data,
where more people live with HIV than any other country.
Our estimates of the relative effectiveness of alternative
approaches can be generalized to many other areas of
southern Africa, but additional work would be needed to
apply this work to regions or countries with a different
epidemic pattern and different costs of health care.
A proliferation of new strategies to control HIV are
developed and tested in South Africa, but economiccircumstances require judicious use of scarce resources.
Developed countries have recently updated guidelines to
recommend universal ART, and the Center for Disease
Control has provided guidance on the use of PrEP in men
who have sex with men [40,41]. Our analysis supports the
new World Health Organization recommendations on
ART for sero-discordant couples, and estimates the value
of extending universal treatment to all infected individuals
[42]. Our work provides new insights into the joint effects
of ART and PrEP in a generalized HIV epidemic, and the
cost-effectiveness of strategies for program scale-up in de-
veloping countries. Implementing the strategies outlined
by these models can lead to better use of scarce resources
and can prevent a significant proportion of new HIV in-
fections, in the long term leading to epidemic control.
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